Thus, the development of drugs or agents targeted on the knots of the mtDNA‐STING‐NLRP3/IL‐1β axis can inhibit neuroinflammation and alleviate the progression of Alzheimer's disease. Here, NLRP3 is linked to early-onset autosomal dominant Alzheimer disease.